# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-269599
Filing Date
2025-11-06
Accepted
2025-11-06 16:18:09
Documents
75
Period of Report
2025-09-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | lctx-20250930.htm iXBRL | 10-Q | 2837769
2 | EX-31.1 | lctx-ex31_1.htm | EX-31.1 | 16632
3 | EX-31.2 | lctx-ex31_2.htm | EX-31.2 | 14792
4 | EX-32.1 | lctx-ex32_1.htm | EX-32.1 | 13941
| Complete submission text file | 0001193125-25-269599.txt |  | 11052822

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
5 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | lctx-20250930.xsd | EX-101.SCH | 1350089
78 | EXTRACTED XBRL INSTANCE DOCUMENT | lctx-20250930_htm.xml | XML | 2101597

Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Filer) CIK: 0000876343 (see all company filings)

EIN.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-12830 | Film No.: 251458563
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)